Oryzon Genomics S.A. (BME:ORY)
Spain · Delayed Price · Currency is EUR 2.580
-0.035 (-1.34%)
Aug 12, 2025, 5:35 PM CET
Blueprint Medicines Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 7.47 | 7.36 | 14.19 | 15.7 | 10.62 | 9.52 | Upgrade | |
Revenue Growth (YoY) | -30.93% | -48.15% | -9.60% | 47.88% | 11.49% | -7.36% | Upgrade |
Cost of Revenue | 0.28 | 0.3 | 0.24 | 0.46 | 0.75 | 0.53 | Upgrade |
Gross Profit | 7.19 | 7.06 | 13.95 | 15.23 | 9.87 | 8.99 | Upgrade |
Selling, General & Admin | 4.3 | 3.64 | 3.61 | 3.57 | 3.67 | 3.69 | Upgrade |
Other Operating Expenses | 7.77 | 7.77 | 14.75 | 17 | 13.07 | 9.45 | Upgrade |
Operating Expenses | 12.22 | 11.56 | 18.51 | 20.73 | 16.88 | 13.29 | Upgrade |
Operating Income | -5.03 | -4.5 | -4.56 | -5.5 | -7.01 | -4.29 | Upgrade |
Interest Expense | -1.03 | -1.23 | -1.89 | -1.12 | -0.46 | -0.47 | Upgrade |
Interest & Investment Income | 0.43 | 0.12 | 0.03 | 0.01 | 0.01 | 0 | Upgrade |
Currency Exchange Gain (Loss) | 0.02 | -0.09 | 0.1 | 0.24 | 0.28 | -0.02 | Upgrade |
Other Non Operating Income (Expenses) | -0 | 0.05 | 0.2 | -0.2 | 0 | - | Upgrade |
EBT Excluding Unusual Items | -5.61 | -5.65 | -6.12 | -6.56 | -7.18 | -4.78 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | - | -0 | -0 | Upgrade |
Asset Writedown | -0 | - | - | - | - | - | Upgrade |
Other Unusual Items | 0.08 | 0.08 | 0.01 | 0.01 | 0.01 | 0 | Upgrade |
Pretax Income | -5.53 | -5.57 | -6.1 | -6.56 | -7.18 | -4.78 | Upgrade |
Income Tax Expense | -1.31 | -1.91 | -2.75 | -2.33 | -2.49 | -1.38 | Upgrade |
Net Income | -4.22 | -3.67 | -3.35 | -4.23 | -4.69 | -3.4 | Upgrade |
Net Income to Common | -4.22 | -3.67 | -3.35 | -4.23 | -4.69 | -3.4 | Upgrade |
Shares Outstanding (Basic) | 78 | 65 | 61 | 55 | 53 | 53 | Upgrade |
Shares Outstanding (Diluted) | 78 | 65 | 61 | 55 | 53 | 53 | Upgrade |
Shares Change (YoY) | 23.15% | 6.35% | 10.10% | 4.80% | - | 15.99% | Upgrade |
EPS (Basic) | -0.05 | -0.06 | -0.06 | -0.08 | -0.09 | -0.06 | Upgrade |
EPS (Diluted) | -0.05 | -0.06 | -0.06 | -0.08 | -0.09 | -0.06 | Upgrade |
Free Cash Flow | -3.03 | -5.69 | -0.57 | -1.92 | -3.8 | -4.97 | Upgrade |
Free Cash Flow Per Share | -0.04 | -0.09 | -0.01 | -0.04 | -0.07 | -0.09 | Upgrade |
Gross Margin | 96.27% | 95.89% | 98.28% | 97.04% | 92.97% | 94.47% | Upgrade |
Operating Margin | -67.30% | -61.18% | -32.16% | -35.02% | -66.07% | -45.06% | Upgrade |
Profit Margin | -56.48% | -49.81% | -23.63% | -26.96% | -44.15% | -35.70% | Upgrade |
Free Cash Flow Margin | -40.53% | -77.32% | -4.05% | -12.25% | -35.82% | -52.20% | Upgrade |
EBITDA | -4.92 | -4.38 | -4.43 | -5.35 | -6.88 | -4.16 | Upgrade |
EBITDA Margin | -65.79% | -59.47% | -31.24% | -34.08% | -64.81% | -43.67% | Upgrade |
D&A For EBITDA | 0.11 | 0.13 | 0.13 | 0.15 | 0.13 | 0.13 | Upgrade |
EBIT | -5.03 | -4.5 | -4.56 | -5.5 | -7.01 | -4.29 | Upgrade |
EBIT Margin | -67.30% | -61.18% | -32.16% | -35.02% | -66.07% | -45.06% | Upgrade |
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.